Case Study | September 08, 2014

Toshiba’s Infinix-i Cardiovascular X-ray Ushers in a New Era of Cost-Effective Disease Treatment

PinnacleHealth developed a successful TAVR program based on the heart team approach and the advanced hybrid OR imaging technology

Infinix-i, TAVR, TOSHIBA

The flexible design of the Infinix-i streamlines procedures and allows operators to obtain a wide range of imaging angles without repositioning the patient.


After several years of trials and increasing clinical use, transcatheter aortic valve replacement (TAVR) has reached a tipping point. It is quickly becoming the standard of care for ill patients suffering from aortic valve stenosis who are not eligible for open heart surgery. Implemented successfully, TAVR procedures improve outcomes and quality of life for patients while reducing costs for hospitals. 

 

To get different clinical disciplines working together, PinnacleHealth created a “heart team” that connects the knowledge base of cardiologists and interventionalists with the expertise of surgeons. As the team worked together and continued to become more familiar with each other and the procedure, the results naturally improved. A by-product of the team’s success was that procedure volumes also increased as the team received more referrals.

For hospitals that are able to push the envelope and innovate with cutting-edge treatments like TAVR, the economic benefits today can be attainable and quantified. 
 
“When TAVR was in its infancy, we developed the relationship between the surgical and percutaneous expertise of our clinicians,” said Brijeshwar Maini, M.D., director of advanced cardiac and endovascular interventional laboratory, director of cardiovascular research and education and medical director of the PinnacleHealth CVI Valve Clinic. “This collaboration enabled us to explore innovative ways to improve patient outcomes with more efficiency.” 
 
The Right Technology 
For its imaging system, PinnacleHealth selected Toshiba’s Infinix-i cardiovascular system for its hybrid OR lab, providing the versatility needed for innovative procedures and dose management optimizing tools for longer procedures. The system offers a mechanical design to provide excellent access and coverage. Its flexible C-arm movement and high-resolution images at various angles enable physicians to conduct advanced TAVR procedures with maximum efficacy. 
 
“The system’s flexible design streamlines procedures, allowing us to obtain a wide range of imaging angles without repositioning the patient,” Maini said. “The Infinix-i, combined with the OR table, produces a hybrid lab that is ready for today’s exams and tomorrow’s innovations.” 
 
State-of-the-art 3mensio and CAAS software are also integrated into the system, making TAVR planning and real-time deployment even more accurate and efficient. 
 
As one of the finest TAVR programs available today, PinnacleHealth has leveraged its heart team approach and the latest technology to achieve fewer readmissions and lower costs.
 
The Business Case for TAVR 
There is often a misconception that newer procedures are more expensive and result in a greater burden for the healthcare system. For TAVR programs, the opposite is true, as these procedures can help reduce readmissions of heart failure patients who are the sickest and most vulnerable to long medical stays. 
 
“For hospitals that are able to push the envelope and innovate with cutting-edge treatments like TAVR, the economic benefits are tangible and quantifiable,” Maini said. 
 
The growth in TAVR procedures and the ability to conduct them with the latest in imaging technology is bringing less invasive, more efficient and lower cost treatments to both patients and healthcare providers.
 

Keys to Developing a Successful TAVR Program:

• Developing the Right Lab: The most important decision for a TAVR program is designing the right lab. Toshiba’s Infinix-i cardiovascular system provides unmatched flexibility in system design and configurations to meet clinicians’ needs to conduct these procedures with ease. 

• Improving Patient Care: Combining long-term strategy and
collaborative planning with innovative, flexible technology can have
a very positive impact on patient care and results. 

• Economic Upside: TAVR programs can help reduce readmissions of heart failure patients. Implemented and managed well, a TAVR program should save hospitals money.

For more information: www.medical.toshiba.com


Related Content

News | Heart Valve Technology

Sept. 1, 2024 — Researchers at UTHealth Houston have identified genetic variants linked to a rare form of bicuspid ...

Home September 04, 2024
Home
News | Heart Valve Technology

June 27, 2024 — The sheer scale of undiagnosed heart valve disease in our aging population has been revealed for the ...

Home June 27, 2024
Home
News | Heart Valve Technology

June 21, 2024 — UC San Francisco interventional cardiologists and interventional echocardiographers recently performed ...

Home June 21, 2024
Home
News | Heart Valve Technology

June 10, 2024 — Atrium Health Sanger Heart & Vascular Institute has successfully completed the first commercial ...

Home June 10, 2024
Home
News | Heart Valve Technology

April 17, 2024 —CPR Therapeutics, Inc. (CPR-T), an early-stage medtech startup funded by the N.I.H and N.S.F to develop ...

Home April 17, 2024
Home
News | Heart Valve Technology

April 1, 2024 — Roughly 25,000 Americans die each year from valvular heart disease, but researchers from Rutgers Health ...

Home April 01, 2024
Home
News | Heart Valve Technology

January 4, 2024 — Findings from a published case series research letter by the Henry Ford Health Structural Heart ...

Home January 04, 2024
Home
News | Heart Valve Technology

December 22, 2023 — TRiCares SAS (“TRiCares”), a privately held pioneer in the field of minimally invasive treatment of ...

Home December 22, 2023
Home
News | Heart Valve Technology

December 18, 2023 — Death rates related to infective endocarditis declined in most adults across the U.S. within the ...

Home December 18, 2023
Home
News | Heart Valve Technology

December 12, 2023 — Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement ...

Home December 12, 2023
Home
Subscribe Now